The Begley paper and the whole debate over reproducibility spawned a worthwhile introspection on behalf of the journals, several of which have adapted the infor

The Begley paper and the whole debate over reproducibility spawned a worthwhile introspection on behalf of the journals, several of which have adapted the information required from authors in response. However, I am distinctly unimpressed by Amgen's failure to live up to the standards it expects of others; not releasing the information required to assess their original claims being their worst offense. In this series, one of the studies, as mentioned in the article, is even a repetition of 4 [1,2,3,4] earlier failed attempts to reproduce the original claim that bexarotene caused a reduction of amyloid in mice [5]; while worthwhile, it is not an impressive contribution. [1] https://www.ncbi.nlm.nih.gov/pubmed/23704555 https://www.ncbi.nlm.nih.gov/pubmed/23704555 [2] https://www.ncbi.nlm.nih.gov/pubmed/23704554 https://www.ncbi.nlm.nih.gov/pubmed/23704554 [3] https://www.ncbi.nlm.nih.gov/pubmed/23704553 https://www.ncbi.nlm.nih.gov/pubmed/23704553 [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086452/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086452/ [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651582/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651582/